Yes. We have run two highly successful Phase 2 trials in AML (2020 & 2023). There are 50 historical trials of bisantene in a wide range of cancers and the drug has gone all the way to approval in AML in France. It is clinically proven to be an effective anti-cancer agent with low cardiotoxicity.
The only thing not known clinically is if bisantrene will be cardioprotective in humans, but the animal models (and human cell models) are scientifically well known to be an accurate model of cardioprotection as they were back engineered to be predictive of human cardioprotection. All the known drugs that protect animal hearts in these models also protect human hearts and vice versa.
Race is a company where doing your own research is highly worthwhile, not least because you will learn a lot and there are many people who will help you if you get stuck.
RAC and NEU, page-8
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.035(2.39%) |
Mkt cap ! $258.2M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.50 | $63.95K | 42.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4063 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 790 | 2 |
View Market Depth
| Last trade - 11.33am 04/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |